Immunogenicity Risk Assessment for Nucleic Acid Therapeutics
Date: September 24, 2026 Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies Description: Nucleic acid therapeutics require new immunogenicity evaluation frameworks, as the safety ...
Advancing Precision Medicine: Oligonucleotide Therapeutics and Genome Editing
Date: June 18, 2026 Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Advancing Precision Medicine: Oligonucleotide Therapeutics and Genome Editing Description: The advent of programmable therapeutics — from oligonucleotide drugs to genome editing technologies — is transforming the treatment landscape for ...
Chance, Choice, and Conviction: A Career in Oligonucleotide Therapeutics
Date: June 4, 2026 Time: 11am-12pm EDT / 5-6pm CEST Register Here Title: Chance, Choice, and Conviction: A Career in Oligonucleotide Therapeutics Description: An insight into how a combination of (taking) chance, role models, mentors, becoming better at making informed decisions, and ...
Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform
Date: May 21, 2026 Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform Description: Dynamic DNA nanotechnology enables the isothermal and enzyme-free exchange of nucleic acid strands. The underlying mechanism of action in ...
Selection of DNA Aptamers to Inhibit TDP-43 Aggregation in ALS
Date: May 7, 2026 Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Selection of DNA Aptamers to Inhibit TDP-43 Aggregation in ALS Description: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of motor neurons. With an ...
Trainee Spotlight Series: 2025 Oligo Meeting Poster Winners 5
Date: April 16, 2026Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Development of an N=1 Therapeutic Antisense Oligonucleotide for a unique UNC13A variant Description: Rare disorders collectively affect 3 to 10% of the population, but treatment options are scarce. Recently, genetic variants ...
Extended Nucleic Acid Therapeutics: Unlocking potential through tiny methylene chemical modifications
Date: April 2, 2026Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Extended Nucleic Acid Therapeutics: Unlocking potential through tiny methylene chemical modifications Description: Modulation of the backbone structures of oligonucleotides has a profound impact on the pharmacokinetics and pharmacodynamics of RNA medicines. In ...
